NEW YORK, Dec. 17 - Functional genomics and proteomics technology developer Agilix has closed a Series B financing round worth $20.8 million, the firm said on Monday.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.